布地奈德治疗小儿呼吸道合胞病毒感染相关喘息的效果及对血清炎性因子的影响
|
摘要
目的分析布地奈德治疗小儿呼吸道合胞病毒(RSV)感染相关喘息的效果和对患儿血清炎性因子的影响。方法选择2016年6月至2017年6月在我院就诊的RSV感染相关喘息患儿84例,按照随机分配原则将其分为对照组和观察组,各42例。对照组给予常规治疗,观察组则在对照组基础上给予布地奈德雾化吸入治疗。比较两组患儿的治疗效果、治疗前、后的血清炎性因子水平、肺功能及出院后6个月、1年的喘息发作和哮喘发生情况。结果观察组患儿的治疗总有效率高于对照组,差异具有统计学意义(P<0.05);治疗前,两组IL-4、IL-12、IL-6、CRP、Ig E、CD3~+、CD4~+、CD8~+水平、CD4~+/CD8~+、FEV1及FEV1/FVC比较,差异均无统计学意义(P>0.05);治疗后,两组患儿IL-4、IL-12、IL-6、CRP、Ig E、CD3~+、CD4~+、CD8~+水平及CD4~+/CD8~+均改善,且观察组优于对照组,差异具有统计学意义(P<0.05);治疗后,两组患儿的FEV1及FEV1/FVC均高于治疗前,且观察组高于对照组,差异具有统计学意义(P<0.05);观察组患儿出院后6个月、1年的喘息发作人数少于对照组,且哮喘发生率低于对照组,差异具有统计学意义(P<0.05)。结论布地奈德治疗小儿RSV感染相关喘息的效果显著,有效改善患儿血清炎性因子水平、临床症状,促进肺功能恢复,并且降低患儿喘息发作几率,值得推广。
Objective To analyze the effect of budesonide on respiratory syncytial virus(RSV) infection-related wheezing in children and its influence on serum inflammatory factors. Methods A total of 84 children with RSV infection-related wheezing in our hospital from June 2016 to June 2017 were selected and divided into control group and observation group according to the principle of random distribution, with 42 cases in each group. The control group received routine treatment, and the observation group was treated with budesonide aerosol inhalation therapy on the basis of the control group. The treatment effects, levels of serum inflammatory factors, lung function before and after treatment,wheezing attack and incidence of asthma at 6 months and 1 year after discharge of the two groups were compared.Results The total effective rate of treatment in the observation group was higher than that in the control group, the difference was statistically significant(P<0.05). Before treatment, there were no significant differences in the levels of IL-4, IL-12, IL-6, CRP, Ig E, CD3~+, CD4~+, CD8~+, CD4~+/CD8~+, FEV1 and FEV1/FVC between the two groups(P>0.05).After treatment, the levels of IL-4, IL-12, IL-6, CRP, Ig E, CD3~+, CD4~+, CD8~+and CD4~+/CD8~+in the two groups improved, and those in the observation group were better than the control group, the differences were statistically significant(P<0.05). After treatment, FEV1 and FEV1/FVC of the two groups were higher than those before treatment, and those in the observation group were higher than the control group, the differences were statistically significant(P<0.05).The numbers of wheezing attacks at 6 months and 1 year after discharge in the observation group were less than those in the control group, and the incidences of asthma were lower than those in the control group, the differences were statistically significant(P <0.05). Conclusion Budesonide is effective in the treatment of children with RSV infection-related wheezing. It can effectively improve levels of serum inflammatory factors, clinical symptoms and promote lung function recovery, and decrease the rate of wheezing in children, which is worth promoting.
Objective To analyze the effect of budesonide on respiratory syncytial virus(RSV) infection-related wheezing in children and its influence on serum inflammatory factors. Methods A total of 84 children with RSV infection-related wheezing in our hospital from June 2016 to June 2017 were selected and divided into control group and observation group according to the principle of random distribution, with 42 cases in each group. The control group received routine treatment, and the observation group was treated with budesonide aerosol inhalation therapy on the basis of the control group. The treatment effects, levels of serum inflammatory factors, lung function before and after treatment,wheezing attack and incidence of asthma at 6 months and 1 year after discharge of the two groups were compared.Results The total effective rate of treatment in the observation group was higher than that in the control group, the difference was statistically significant(P<0.05). Before treatment, there were no significant differences in the levels of IL-4, IL-12, IL-6, CRP, Ig E, CD3~+, CD4~+, CD8~+, CD4~+/CD8~+, FEV1 and FEV1/FVC between the two groups(P>0.05).After treatment, the levels of IL-4, IL-12, IL-6, CRP, Ig E, CD3~+, CD4~+, CD8~+and CD4~+/CD8~+in the two groups improved, and those in the observation group were better than the control group, the differences were statistically significant(P<0.05). After treatment, FEV1 and FEV1/FVC of the two groups were higher than those before treatment, and those in the observation group were higher than the control group, the differences were statistically significant(P<0.05).The numbers of wheezing attacks at 6 months and 1 year after discharge in the observation group were less than those in the control group, and the incidences of asthma were lower than those in the control group, the differences were statistically significant(P <0.05). Conclusion Budesonide is effective in the treatment of children with RSV infection-related wheezing. It can effectively improve levels of serum inflammatory factors, clinical symptoms and promote lung function recovery, and decrease the rate of wheezing in children, which is worth promoting.
引文
[1]孙向阳.布地奈德治疗儿童RSV感染相关喘息的疗效及其对血清炎症介质水平的影响[J].实用临床医药杂志,2014,18(15):51.
[2]王建梅.布地奈德治疗儿童呼吸道合胞病毒(RSV)感染相关喘息的疗效及其对血清炎症介质水平的影响[J].世界最新医学信息文摘,2017,17(a1):129.
[3]李积涛.布地奈德治疗小儿呼吸道合胞病毒感染相关喘息的临床疗效[J].中国实用医药,2017,12(31):114-115.
[4]陈瑜,肖劲花,黄冬蕾,等.孟鲁司特钠联合雾化吸入布地奈德对RSV毛细支气管炎的疗效及血清炎症因子的影响[J].海南医学,2018,29(9):34-36.
[5]刘雪茹,胡艳,陈和斌,等.孟鲁司特钠治疗儿童呼吸道合胞病毒感染毛细支气管炎的疗效及对炎症标志物的影响[J].中华医院感染学杂志,2018,28(2):276-279.
[6]钟蒙蒙.布地奈德混悬液雾化吸入联合妥洛特罗贴剂治疗小儿喘息性肺炎的疗效及其对炎性因子的影响[J].中国基层医药,2017,24(15):2308.
[7]杨秋丽,郑小翠.布地奈德混悬液联合妥洛特罗治疗小儿喘息性肺炎的疗效及对血清细胞因子水平炎症指标的影响[J].山西医药杂志,2017,46(1):73-75.
[8]李吉红,张红.布地奈德雾化吸入对支原体肺炎患儿临床疗效及血清炎性因子水平的影响[J].河北医学,2017,23(1):105-108.
[9]刘调侠,李延琴.孟鲁司特钠联合布地奈德治疗小儿毛细支气管炎的临床疗效及其对炎症因子的影响[J].儿科药学杂志,2017,23(6):27-30.
[10]柴斌英,万俊,包志丹,等.布地奈德雾化剂联合孟鲁司特钠治疗小儿哮喘患者的疗效及对血清炎性因子的影响[J].河北医药,2018,40(13):1969-1971,1975.
[11]倪树芳,姚文江.不同剂量布地奈德混悬液雾化吸入对婴幼儿喘息性支气管炎疗效及细胞因子的影响[J].中国妇幼保健,2015,30(28):4901-4903.
[12]寇志军.双黄连联合布地奈德雾化吸入治疗对肺炎患儿免疫功能和血清炎性因子的影响[J].中国药物经济学,2017,12(1):66-68.
[13]董艳鹏.布地奈德对轻度持续性支气管哮喘患儿血清MMP、炎性因子、痰液EOS的影响[J].齐齐哈尔医学院学报,2017,38(24):2911-2912.
[14]宋亚尧.雾化吸入布地奈德混悬液联合妥洛特罗治疗小儿喘息性肺炎的临床效果观察[J].中国医药指南,2017,15(21):99-100.
[15]万燕婷,邹琪,李薇,等.雾化吸入布地奈德混悬液联合妥洛特罗治疗小儿喘息性肺炎的临床疗效观察[J].国际呼吸杂志,2015,35(16):1210-1212.
[2]王建梅.布地奈德治疗儿童呼吸道合胞病毒(RSV)感染相关喘息的疗效及其对血清炎症介质水平的影响[J].世界最新医学信息文摘,2017,17(a1):129.
[3]李积涛.布地奈德治疗小儿呼吸道合胞病毒感染相关喘息的临床疗效[J].中国实用医药,2017,12(31):114-115.
[4]陈瑜,肖劲花,黄冬蕾,等.孟鲁司特钠联合雾化吸入布地奈德对RSV毛细支气管炎的疗效及血清炎症因子的影响[J].海南医学,2018,29(9):34-36.
[5]刘雪茹,胡艳,陈和斌,等.孟鲁司特钠治疗儿童呼吸道合胞病毒感染毛细支气管炎的疗效及对炎症标志物的影响[J].中华医院感染学杂志,2018,28(2):276-279.
[6]钟蒙蒙.布地奈德混悬液雾化吸入联合妥洛特罗贴剂治疗小儿喘息性肺炎的疗效及其对炎性因子的影响[J].中国基层医药,2017,24(15):2308.
[7]杨秋丽,郑小翠.布地奈德混悬液联合妥洛特罗治疗小儿喘息性肺炎的疗效及对血清细胞因子水平炎症指标的影响[J].山西医药杂志,2017,46(1):73-75.
[8]李吉红,张红.布地奈德雾化吸入对支原体肺炎患儿临床疗效及血清炎性因子水平的影响[J].河北医学,2017,23(1):105-108.
[9]刘调侠,李延琴.孟鲁司特钠联合布地奈德治疗小儿毛细支气管炎的临床疗效及其对炎症因子的影响[J].儿科药学杂志,2017,23(6):27-30.
[10]柴斌英,万俊,包志丹,等.布地奈德雾化剂联合孟鲁司特钠治疗小儿哮喘患者的疗效及对血清炎性因子的影响[J].河北医药,2018,40(13):1969-1971,1975.
[11]倪树芳,姚文江.不同剂量布地奈德混悬液雾化吸入对婴幼儿喘息性支气管炎疗效及细胞因子的影响[J].中国妇幼保健,2015,30(28):4901-4903.
[12]寇志军.双黄连联合布地奈德雾化吸入治疗对肺炎患儿免疫功能和血清炎性因子的影响[J].中国药物经济学,2017,12(1):66-68.
[13]董艳鹏.布地奈德对轻度持续性支气管哮喘患儿血清MMP、炎性因子、痰液EOS的影响[J].齐齐哈尔医学院学报,2017,38(24):2911-2912.
[14]宋亚尧.雾化吸入布地奈德混悬液联合妥洛特罗治疗小儿喘息性肺炎的临床效果观察[J].中国医药指南,2017,15(21):99-100.
[15]万燕婷,邹琪,李薇,等.雾化吸入布地奈德混悬液联合妥洛特罗治疗小儿喘息性肺炎的临床疗效观察[J].国际呼吸杂志,2015,35(16):1210-1212.
© 2004-2018 中国地质图书馆版权所有 京ICP备05064691号 京公网安备11010802017129号 地址：北京市海淀区学院路29号 邮编：100083 电话：办公室：(+86 10)66554848；文献借阅、咨询服务、科技查新：66554700 |